Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study

Abstract

Background: Type 2 diabetes (T2D) is a known risk factor for cardiovascular disease (CVD), and CVD is a major cause of mortality in patients with T2D. The CAPTURE study investigated the contemporary (2019) prevalence of established CVD in adults with T2D around the world. We report the findings from Brazil.

Methods: The multinational, non-interventional, cross-sectional CAPTURE study was conducted across 13 countries from five continents. The current manuscript explores data for the CAPTURE study sample in Brazil. Standardized demographic and clinical data were collected from adults with T2D aged ≥ 18 years attending a single routine healthcare visit in primary or specialized care between December 2018 and September 2019. Data were analyzed descriptively.

Results: Data from 912 adults with T2D were collected in the CAPTURE study in Brazil, with 822 patients from primary care and 90 patients from specialized care. Median (interquartile range [IQR]) patient characteristics were as follows: age 64 years (57; 71), diabetes duration 11 years (6; 19), glycated hemoglobin 7.7% (6.7; 9.1), and body mass index 29.5 kg/m2 (26.4; 33.5); 59% were female. The CVD prevalence and atherosclerotic CVD prevalence in the Brazil sample were 43.9% (95% confidence interval [CI] 40.9; 46.8) and 37.6% (95% CI 34.7; 40.5), respectively. The majority of patients with CVD had atherosclerotic CVD (85.8%). For the specific CVD subtypes, coronary heart disease prevalence was 27.9% (95% CI 25.2; 30.5), heart failure was 12.4% (95% CI 10.4; 14.4), cerebrovascular disease was 8.7% (95% CI 6.8; 10.5), and carotid artery disease was 3.4% (95% CI 2.3; 4.5). Glucagon-like peptide-1 receptor agonists and/or sodium-glucose co-transporter-2 inhibitors with proven cardiovascular benefit were prescribed to 15.5% of patients with CVD, compared with 18.4% of patients without CVD.

Conclusions: CAPTURE was the first multinational, standardized study to provide contemporary data on CVD prevalence in adults with T2D in Brazil, and it demonstrated that almost one in two adults with T2D had established CVD. Except for carotid artery disease, the prevalence of all CVD subtypes in adults with T2D in Brazil appeared higher than the global CAPTURE prevalence. Trial registration NCT03786406, NCT03811288.

Keywords: Atherosclerosis; Brazil; Cardiovascular disease; Cross-sectional study; Prevalence; Type 2 diabetes.

Conflict of interest statement

SV—Research grants: Novo Nordisk, Biomm, Bayer and Cristalia; honoraria for consultancy or giving lectures: AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Novartis; he is also the Editor-in-Chief of Diabetology & Metabolic Syndrome and this article was independently handled by the Deputy Editor-in-Chief. AV—Advisory Board: Novo Nordisk, Sanofi, Biomm, Abbott Diabetes Care, and Medtronic; speaker: Novo Nordisk, Sanofi, Biomm, Abbott Diabetes Care, Servier, MSD, Medtronic, Lilly, and AstraZeneca; research Grants: Novo Nordisk, AstraZeneca, and Lilly. MS—Employee of and shareholder in Novo Nordisk. DP—Research grants: Novo Nordisk, Bayer, Boehringer Ingelheim, Novartis, Daiichi-Sankyo, Amgen, Vifor-Pharma, and AstraZeneca; advisory board: Servier and Bayer.

© 2022. The Author(s).

Figures

Fig. 1

Prevalence of CVD in Brazil in patients with T2D by CVD subtype and diagnoses. Diagnoses are not mutually exclusive; one participant may have multiple diagnoses. †Categorized as ASCVD. ‡Included conduction abnormalities. ASCVD: atherosclerotic CVD; AV: atrioventricular; CHD: coronary heart disease; CI: confidence interval; CVD: cardiovascular disease; PAD: peripheral artery disease; SND: sinus node dysfunction; T2D: type 2 diabetes